{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pelvic-inflammatory-disease/prescribing-information/ceftriaxone/","result":{"pageContext":{"chapter":{"id":"33b4bf00-1e15-50d8-ae8e-cae48e64e869","slug":"ceftriaxone","fullItemName":"Ceftriaxone","depth":2,"htmlHeader":"<!-- begin field beefa537-9e00-4145-80a5-a9470106d3df --><h2>Ceftriaxone</h2><!-- end field beefa537-9e00-4145-80a5-a9470106d3df -->","summary":"","htmlStringContent":"<!-- begin item 368ddcd7-3929-4d09-8e7e-a9470106d0f6 --><!-- end item 368ddcd7-3929-4d09-8e7e-a9470106d0f6 -->","topic":{"id":"9f0279a4-2834-5e5a-bcac-8bf82aa33bc3","topicId":"c3fb3eae-a416-4305-9bb7-f8c4a28827e3","topicName":"Pelvic inflammatory disease","slug":"pelvic-inflammatory-disease","lastRevised":"Last revised in June 2019","chapters":[{"id":"5f211e92-2994-512e-b182-200dcee7cfe5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1d99b28e-147a-50d9-b809-b2997de385cd","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"edca47ac-ad32-5cdc-b5b0-044c08354023","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"61747f80-342b-5eee-9f57-5585e2e266a1","slug":"changes","fullItemName":"Changes"},{"id":"34323845-1d0f-5dd2-9d12-aa4195ea061a","slug":"update","fullItemName":"Update"}]},{"id":"41aa50e1-c3d6-5af5-8d64-bf56566bcf4a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5485b6d3-ad41-5a4f-8068-3927541fc840","slug":"goals","fullItemName":"Goals"},{"id":"8e512ac7-b08d-5db9-b36c-0b6bf6adeab6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"16ee94a8-ef4e-5d73-9aab-3a7ad56481d0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"00ebd775-876e-52d3-8917-e865f1ca24ac","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"00b18462-2317-5fa1-964d-480008f24d93","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a76f3e2f-4836-5bfb-8b3d-65126afcd379","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b5957fa8-3b35-540f-93d4-a16fe133bcd7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7ffd6d91-45b2-5f09-8a72-1269c1cf4194","slug":"definition","fullItemName":"Definition"},{"id":"8d2eecb8-da49-56f0-b0f3-512e1ef7da78","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"cd56fa88-472b-5053-8750-7288cff96a45","slug":"incidence","fullItemName":"Incidence"},{"id":"eae17c05-1a5f-5d75-be7c-b0e30fbc5151","slug":"complications","fullItemName":"Complications"}]},{"id":"13e64b0f-f012-5f38-978c-906828fd01c0","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6bef4b1a-5873-5e3c-a07f-a72df2163883","slug":"assessment","fullItemName":"Assessment"},{"id":"44e7ae24-ecb6-5611-a376-e300900a9915","slug":"investigations","fullItemName":"Investigations"},{"id":"f2d53656-5ddd-5cac-a2f0-5155e3e4816f","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"04b9a20a-4646-577d-9db4-a82fad1f1122","fullItemName":"Management","slug":"management","subChapters":[{"id":"db64e69d-0dae-56cc-ac8c-111a4ae832f9","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"c9c97d1d-e768-53f0-8f37-0186133444ed","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c6b38292-e76f-5f9e-b08f-9038f7a1e33c","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"33b4bf00-1e15-50d8-ae8e-cae48e64e869","slug":"ceftriaxone","fullItemName":"Ceftriaxone"},{"id":"07bec723-0e9e-5a18-9e33-37a6b08715b1","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"407d577d-6898-50ed-a49b-95ad0651ada7","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"631d3af6-f8a7-581f-9d98-a24412ab54f1","slug":"moxifloxacin","fullItemName":"Moxifloxacin"},{"id":"f5753d3f-d2cb-58c0-a3ba-9ea9ad6651ba","slug":"ofloxacin","fullItemName":"Ofloxacin"}]},{"id":"f7cbd9f8-3abb-50db-95c5-bb3b61731818","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"6b504e72-502e-54b1-8c90-a7bc3421bd9f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c908da70-e8da-577d-aa14-2a477f0bc1cf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"07e835ee-992a-5310-a2e1-6c64c3dcf57f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"81326348-513f-5842-87bb-414706046cb1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0f235ae8-132c-5727-bb43-da1eaf2b8a7d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c0ba9a54-ce24-5b78-a3fa-c48701375f1c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8c22c848-92a6-5535-b584-48002acef06e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"c9c97d1d-e768-53f0-8f37-0186133444ed","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"4cf15d53-3278-579e-8e0f-5f1e0df60e52","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 51a10b0c-2e10-40a2-a3be-a94701650053 --><h3>What are the contraindications and cautions?</h3><!-- end field 51a10b0c-2e10-40a2-a3be-a94701650053 -->","summary":"","htmlStringContent":"<!-- begin item e9ee395b-c71b-4ae8-80a8-a9470164ff22 --><!-- begin field f4719b4c-c0f8-4f28-a712-a94701650053 --><ul><li><strong>Do not prescribe ceftriaxone to people:</strong><ul><li>With known hypersensitivity to any cephalosporins, beta-lactam antibiotics, or penicillin.</li><li>Note that:<ul><li>Gastrointestinal adverse effects alone (for example nausea, vomiting, or diarrhoea) do <em>not </em>constitute an allergy to penicillin.</li><li>About 0.5–6.5% of penicillin-sensitive people will also be allergic to the cephalosporins.</li></ul></li></ul></li><li><strong>Prescribe ceftriaxone with caution:</strong><ul><li>If a cephalosporin is essential in people with a history of immediate hypersensitivity to penicillin.</li><li>In people with a history of:<ul><li>Gastrointestinal disorders (for example, colitis).</li><li>Hypercalciuria.</li><li>Kidney stones.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BNF 75, 2018</a>]</p><!-- end field f4719b4c-c0f8-4f28-a712-a94701650053 --><!-- end item e9ee395b-c71b-4ae8-80a8-a9470164ff22 -->","subChapters":[]},{"id":"5990b14c-7447-525c-bbb6-fac9f2015cb4","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 70960efa-6a4b-4110-919a-a9470165179f --><h3>What are the adverse effects?</h3><!-- end field 70960efa-6a4b-4110-919a-a9470165179f -->","summary":"","htmlStringContent":"<!-- begin item bfefa1bb-a6c8-4c0e-95d3-a947016516bc --><!-- begin field a7baef63-8efb-42e8-bc7b-a9470165179f --><ul><li><strong>Adverse effects of ceftriaxone include:</strong><ul><li><strong>Common or very common</strong><ul><li>Precipitation of calcium ceftriaxone in gall bladder — consider discontinuation if symptomatic.</li><li>Precipitation of calcium ceftriaxone in urine (particularly in very young, dehydrated, or those who are immobilized) —consider discontinuation if symptomatic.</li></ul></li><li><strong>Uncommon</strong> — gential fungal infection.</li><li><strong>Rare </strong>— bronchospasm, glycosuria, haematuria, and prolongation of prothrombin time.</li><li><strong>Frequency not known </strong>— convulsion, glossitis, oliguria, pancreatitis, stomatitis, toxic epidermal necrolysis, and vertigo.</li></ul></li><li><strong>Adverse effects of all cephalosporins include:</strong><ul><li><strong>Rare </strong>— antibiotic-associated colitis.</li><li><strong>Frequency not known:</strong><ul><li>Abdominal discomfort, diarhoea, nausea, vomiting.</li><li>Agranulocytosis, aplastic anaemia, blood disorders, eosinophilia, haemolytic anaemia, leucopenia, thrombocytopenia</li><li>Confusion, nervousness, sleep disturbances.</li><li>Disturbances in liver enzymes.</li><li>Transient cholestatic jaundice, transient hepatitis.</li><li>Dizziness, hallucinations, headache.</li><li>Hyperactivity.</li><li>Hypertonia.</li><li>Reversible interstitial nephritis.</li><li>Serum sickness-like reactions with rashes, fever and arthralgia.</li><li>Pruritus, rashes, urticaria, anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BNF 75, 2018</a>]</p><!-- end field a7baef63-8efb-42e8-bc7b-a9470165179f --><!-- end item bfefa1bb-a6c8-4c0e-95d3-a947016516bc -->","subChapters":[]},{"id":"8dbe63b8-4469-59be-9413-a3f58112f7ff","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field fd219d3e-69bb-4a99-8fdf-a94701651cc9 --><h3>What are the drug interactions?</h3><!-- end field fd219d3e-69bb-4a99-8fdf-a94701651cc9 -->","summary":"","htmlStringContent":"<!-- begin item c4181536-d656-4453-b7d7-a9470165192e --><!-- begin field 7bb4825f-3114-496b-9a7d-a94701651cc9 --><ul><li><strong>Drug interactions of </strong><strong>ceftriaxone</strong><strong><strong> </strong>include:</strong><ul><li><strong>Warfarin</strong> — ceftriaxone may enhance the anticoagulant effect of warfarin.<ul><li>Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li></ul></li><li><strong>Calcium chloride and calcium gluconate </strong>— ceftriaxone increases the risk of cardio-respiratory arrest when given with calcium chloride or calcium gluconate.<ul><li>The manufacturer advises that concurrent use should be avoided.</li></ul></li></ul></li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are <em>not</em> required during or after courses of ceftriaxone [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">FSRH, 2017</a>].<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>For a complete list of possible drug interactions of </strong><strong>ceftriaxone</strong><strong>, </strong>see the <a data-hyperlink-id=\"5203f819-92f2-4ec0-b745-a94a00ee63e5\" href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) and the <a data-hyperlink-id=\"3eb72c95-6193-4a8b-81f0-a94a00ee64a5\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BNF 75, 2018</a>]</p><!-- end field 7bb4825f-3114-496b-9a7d-a94701651cc9 --><!-- end item c4181536-d656-4453-b7d7-a9470165192e -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}